CGTX

Cognition Therapeutics (CGTX)

About Cognition Therapeutics (CGTX)

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system, or CNS, and retina. It offers the CT1812 which aims to restore the damaged cellular processes that drive diseases such as Alzheimer’s disease, dry age-related macular degeneration, geographic atrophy and other conditions. The company was founded by Franz F. Hefti, Gilbert M. Rishton, and Susan M. Catalano on August 21, 2007 and is headquartered in Purchase, NY.

Details

Daily high

Daily low

Price at open

52 Week High

$3.83

52 Week Low

$0.27

Market cap

150.4M

Dividend yield

0.00%

Volume

20,037

Avg. volume

1.4M

P/E ratio

-6.52

Cognition Therapeutics News